Argireline (Acetyl Hexapeptide-8) — The World”s Most Commercially Successful Cosmetic Peptide
Acetyl Hexapeptide-8, marketed as Argireline and also referenced as Acetyl Hexapeptide-3, is a synthetic hexapeptide that reduces expression-line depth by interfering with neuromuscular signal transmission at the pre-synaptic level. Originally developed by Lipotec (Barcelona), it became the first peptide active widely adopted by the global cosmetics industry. Over 60% of anti-wrinkle products that contain peptides now incorporate Argireline or one of its derivatives. TCS NEXUS S.L. supplies research-grade and bulk-cosmetic-grade Argireline from our warehouse in Valencia, Spain.
Technical Specifications
| Parameter | Value |
|---|---|
| INCI Name | Acetyl Hexapeptide-8 (Acetyl Hexapeptide-3, Argireline) |
| CAS Number | 616204-22-9 |
| Molecular Weight | 888.04 g/mol |
| Sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 |
| Purity (HPLC) | ≥ 99% |
| Appearance | White to off-white lyophilized powder |
| Solubility | Water-soluble |
| Recommended pH | 5.0 – 7.0 |
| Addition Temperature | Below 40 °C |
| Storage | 2 – 8 °C, sealed, protect from light |
Mechanism of Action
Argireline mimics the N-terminal segment of SNAP-25, one of the three proteins that assemble the SNARE complex at the neuromuscular junction. By competing for a binding position on the SNARE assembly, it reduces vesicle docking efficiency. Fewer docked vesicles means less acetylcholine release into the synaptic cleft, which in turn decreases the force of muscle contraction. The net result is a measurable relaxation of facial musculature — particularly the frontalis (forehead) and orbicularis oculi (crow”s feet) — without any injectable procedure.
This pre-synaptic mechanism is complementary to post-synaptic approaches such as Dipeptide Diaminobutyroyl Benzylamide Diacetate (SYN-AKE), which acts as a waglerin-1 analogue at the nicotinic acetylcholine receptor. Combining both in a single formulation addresses both sides of the neuromuscular junction and has become standard practice in advanced anti-aging serums.
Clinical Efficacy Data
In a controlled 30-day clinical study with 20 volunteers, topical application of a 10% Argireline solution reduced periorbital wrinkle depth by 30% as measured by silicone-replica profilometry. A separate trial using a 5% solution demonstrated a 17% reduction in wrinkle depth within 15 days. Efficacy is most pronounced on dynamic expression lines — forehead furrows, glabellar lines, and crow”s feet — where repetitive muscle contraction is the primary aetiological factor.
Formulation Guidelines
The standard commercial solution of Argireline contains approximately 0.005% active peptide in water. Finished cosmetic products typically incorporate 3 – 10% of this solution, yielding a final peptide concentration of roughly 0.05 – 0.5% depending on dilution. Add the peptide solution during the cool-down phase of emulsion manufacture, below 45 °C, to preserve bioactivity. The working pH range is 5.0 – 7.0. Argireline is compatible with most standard cosmetic ingredients including humectants, emollients, emulsifiers, and preservative systems. Avoid combining with strong oxidising agents (peroxides, hypochlorites) that can degrade the methionine residue in the sequence.
For enhanced anti-wrinkle performance, formulators routinely combine Argireline with Acetyl Octapeptide-3 (SNAP-8), which targets the same SNARE pathway with higher affinity, and Pentapeptide-18 (Leuphasyl), which acts via the enkephalin receptor to reduce catecholamine release. Layering pre-synaptic and post-synaptic peptides — for example Argireline + SYN-AKE — covers both halves of the neuromuscular junction.
Commercial and Supply Information
Argireline remains the single most commercially successful cosmetic peptide worldwide. European wholesale pricing for the standard aqueous solution typically ranges from 300 to 500 EUR/kg; pure lyophilised peptide commands significantly higher pricing depending on volume and purity grade. TCS NEXUS S.L. holds ready stock in Valencia, Spain with standard European delivery in 5 – 7 business days. All batches ship with a full Certificate of Analysis (CoA) including HPLC chromatograms, mass spectrometry confirmation, amino acid analysis, and endotoxin testing. Sample quantities are available for formulation trials.
Related Peptide Products
- Dipeptide Diaminobutyroyl Benzylamide Diacetate (SYN-AKE) — post-synaptic neuromuscular peptide, waglerin-1 analogue
- Acetyl Octapeptide-3 (SNAP-8) — extended-sequence SNARE inhibitor with higher binding affinity than Argireline
- Pentapeptide-18 (Leuphasyl) — enkephalin-receptor agonist that reduces catecholamine-mediated muscle contraction
Further reading: See also: Cosmetic Peptides Technical Guide | Anti-Aging Peptide Comparison
Frequently Asked Questions
Can Argireline replace Botox?
Argireline and botulinum toxin both reduce acetylcholine release, but through different mechanisms and with different potencies. Botox cleaves SNAP-25 enzymatically, producing near-complete local paralysis. Argireline competes for SNARE assembly, producing a partial, reversible relaxation. Clinical data shows up to 30% wrinkle-depth reduction with topical Argireline — meaningful, but not equivalent to injectable neurotoxin. Argireline is best positioned as a daily-maintenance active between injection cycles, or as a non-invasive alternative for consumers who decline injectable treatments.
Does Argireline work on all wrinkle types?
Argireline is most effective on dynamic expression lines caused by repetitive muscle contraction — forehead lines, crow”s feet, and glabellar furrows. Static wrinkles caused by photoageing, collagen loss, or gravitational sagging respond less well because their origin is structural rather than muscular. For static wrinkles, combine Argireline with collagen-stimulating peptides such as palmitoyl tripeptide-1 or copper peptide GHK-Cu.
Can I combine Argireline with retinol?
Yes. Argireline and retinol operate through entirely unrelated pathways and are chemically compatible at the pH ranges used in cosmetic formulations (pH 5.0 – 7.0 for Argireline, pH 5.5 – 6.5 for encapsulated retinol). Add Argireline in the aqueous phase below 40 °C and retinol in the oil or encapsulated phase. No antagonistic interaction has been reported in published stability or efficacy studies.
How long before I see results?
Published data shows measurable wrinkle-depth reduction within 15 days at 5% solution concentration, and 30% reduction at 30 days with 10% solution concentration. Consumer-perceptible improvement typically becomes noticeable between weeks two and four of twice-daily application. Continued use is required to maintain the effect, as the SNARE-competition mechanism is fully reversible.
What is the minimum order quantity (MOQ)?
TCS NEXUS S.L. offers Argireline with no fixed MOQ for sample and trial quantities. Production-scale orders typically start at 1 kg of solution. Contact our Valencia team for custom packaging, white-label options, or bulk pricing on orders above 50 kg.
Technical Support and Samples
Request COA documents, sample availability, or support for custom synthesis.
Frequently Asked Questions
Do you provide COA documents for Argireline (Acetyl Hexapeptide-8) Europe?
Yes. Each lot can be supplied with a Certificate of Analysis, HPLC purity data, and relevant quality-control results for technical review.
Are samples available for Argireline (Acetyl Hexapeptide-8) Europe?
Yes. Sample availability can be confirmed for formulation screening and internal evaluation before a commercial order is placed.
What is the delivery lead time for Argireline (Acetyl Hexapeptide-8) Europe?
For stocked material in Valencia, EU delivery is typically 5 to 7 business days. Final timing depends on destination and requested volume.
Do you also support custom synthesis and technical inquiries?
Yes. The team can help with custom synthesis, raw-material selection, technical documentation, and supply planning.